Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022
- PMID: 35176008
- PMCID: PMC8853473
- DOI: 10.15585/mmwr.mm7107e1
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022
Abstract
During September 22, 2021-February 6, 2022, approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.* The Food and Drug Administration (FDA) has authorized a booster dose of either the same product administered for the primary series (homologous) or a booster dose that differs from the product administered for the primary series (heterologous). These booster authorizations apply to all three COVID-19 vaccines used in the United States (1-3).† The Advisory Committee on Immunization Practices (ACIP) recommended preferential use of an mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer-BioNTech]) for a booster, even for persons who received the Ad26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine for their single-dose primary series.§ To characterize the safety of COVID-19 vaccine boosters among persons aged ≥18 years during September 22, 2021-February 6, 2022, CDC reviewed adverse events and health impact assessments following receipt of a booster that were reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA. Among 721,562 v-safe registrants aged ≥18 years who reported receiving a booster, 88.8% received homologous COVID-19 mRNA vaccination. Among registrants who reported a homologous COVID-19 mRNA booster dose, systemic reactions were less frequent following the booster (58.4% [Pfizer-BioNTech] and 64.4% [Moderna], respectively) than were those following dose 2 (66.7% and 78.4%, respectively). The adjusted odds of reporting a systemic reaction were higher following a Moderna COVID-19 vaccine booster, irrespective of the vaccine received for the primary series. VAERS has received 39,286 reports of adverse events after a COVID-19 mRNA booster vaccination for adults aged ≥18 years, including 36,282 (92.4%) nonserious and 3,004 (7.6%) serious events. Vaccination providers should educate patients that local and systemic reactions are expected following a homologous COVID-19 mRNA vaccine booster; however, these reactions appear less common than those following dose 2 of an mRNA-based vaccine. CDC and FDA will continue to monitor vaccine safety and provide data to guide vaccine recommendations and protect public health.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Philip G. Blanc reports stock ownership in Community Health Systems, Inc. No other potential conflicts of interest were reported.
Figures
![FIGURE](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8853473/bin/mm7107e1-F.gif)
Similar articles
-
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.MMWR Morb Mortal Wkly Rep. 2022 Nov 4;71(44):1401-1406. doi: 10.15585/mmwr.mm7144a3. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36327162 Free PMC article.
-
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.MMWR Morb Mortal Wkly Rep. 2023 Jan 13;72(2):39-43. doi: 10.15585/mmwr.mm7202a5. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36634021 Free PMC article.
-
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.MMWR Morb Mortal Wkly Rep. 2022 Mar 4;71(9):347-351. doi: 10.15585/mmwr.mm7109e2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35239637 Free PMC article.
-
Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.Vaccine. 2024 Apr 2;42(9):2380-2384. doi: 10.1016/j.vaccine.2024.02.084. Epub 2024 Mar 11. Vaccine. 2024. PMID: 38462432 Review.
-
Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.Vaccine. 2023 Jul 5;41(30):4422-4430. doi: 10.1016/j.vaccine.2023.06.023. Epub 2023 Jun 14. Vaccine. 2023. PMID: 37321898 Free PMC article. Review.
Cited by
-
Understanding the factors associated with COVID-19 vaccine hesitancy in Venezuela.BMC Public Health. 2024 Apr 23;24(1):1117. doi: 10.1186/s12889-024-18598-4. BMC Public Health. 2024. PMID: 38654278 Free PMC article.
-
COVID-19 vaccination in healthcare workers: Long-term benefits and protection.Cent Eur J Immunol. 2023;48(4):311-321. doi: 10.5114/ceji.2023.134250. Epub 2024 Oct 10. Cent Eur J Immunol. 2023. PMID: 38558566 Free PMC article.
-
Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System.Pharmaceuticals (Basel). 2024 Mar 10;17(3):356. doi: 10.3390/ph17030356. Pharmaceuticals (Basel). 2024. PMID: 38543142 Free PMC article.
-
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.Vaccines (Basel). 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118. Vaccines (Basel). 2024. PMID: 38400102 Free PMC article.
-
Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador.Clin Exp Vaccine Res. 2024 Jan;13(1):35-41. doi: 10.7774/cevr.2024.13.1.35. Epub 2024 Jan 31. Clin Exp Vaccine Res. 2024. PMID: 38362366 Free PMC article.
References
-
- Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine letter of authorization. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/150386/download
-
- Food and Drug Administration. Moderna COVID-19 vaccine decision memorandum. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/154405/download
-
- Food and Drug Administration. Janssen COVID-19 vaccine decision memorandum. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/154359/download
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical